This reduction from previous guidance primarily affects the successful execution of cost optimization initiatives, discipline expense management, and a more efficient allocation of resources across the organization.

Aug 14, 2025 / receipt, needs a key / Henry Du, CFO | earnings call 2025-08-14 | transcript 12ac0a2b-b80d-416c-a436-e1823f9db4af | chars 9091-9306 | segment 9

The Company continues to manage expenses judiciously while preparing to take advantage of emerging opportunities in the long-term care market.

ir_statement / Sep 14, 2026 / receipt

The increase reflects higher SG&A costs as we expanded commercial launch activities and scaled operations to support growth.

ir_statement / Sep 14, 2026 / receipt

Our commercial footprint continues to expand rapidly. We engaged 2,038 homes in Q3, bringing total launch-to-date reach to 2,942 unique homes.

ir_statement / Sep 14, 2026 / receipt

We now expect full-year 2025 operating expenses to be in the range of $28 million to $30 million, a reduction from prior guidance due to disciplined cost management, renegotiation of contracts, reass

ir_statement / Sep 14, 2026 / receipt

Operational learnings from payer interactions are streamlining prior authorization processes, improving speed to therapy and access.

ir_statement / Sep 14, 2026 / receipt

We anticipate signing a second PBM contract by year-end 2025, with unrestricted coverage emerging approximately two quarters later.

ir_statement / Sep 14, 2026 / receipt

We expanded our reimbursement team to better support homes processing prior authorizations, enabling tighter alignment with customers and faster issue resolution.

ir_statement / Sep 14, 2026 / receipt

That’s why we’ve expanded our reimbursement team.

ir_statement / Sep 14, 2026 / receipt

One can launch into that market with a very small sales force, which lowers the resource needs for the company.

ir_statement / Sep 14, 2026 / receipt

We do have future plans to launch into neurology, which represents another $1.5 billion opportunity for the company, and we'll evaluate whether we choose to do that by ourselves or we partner.

ir_statement / Sep 14, 2026 / receipt

We've partnered in Asia, specifically China and other Asian countries with a company called CMS Pharma. They are petitioning the Chinese regulatory authorities for Zunveyl approval. And we plan to sub

ir_statement / Sep 14, 2026 / receipt

Yes, larger sales force marketing to the geriatric psychiatry community

ir_statement / Sep 14, 2026 / receipt